Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ANTABIO

Home Clinical Trial Sponsors and OrganizationsANTABIO

ANTABIO

CHEZ BIOSTEP, Labege, Occitanie, France

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

6

1 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

6

100.0%

Trial Status Distribution

Active, not recruiting

1

16.7%

Completed

3

50.0%

Recruiting

1

16.7%

Suspended

1

16.7%

Clinical Trials

Trials sponsored by this organization (6)

A Phase 1, Open-Label, Non-Randomized, Single-Center, Single-Dose Study to Assess the Pharmacokinetics and Safety of ANT3310 Combined with Meropenem Administered as a Single Intravenous Infusion to Adult Subjects with Renal Function Impairment

48 participants

A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.

Jun 202640 participants

Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants

Apr 202526 participants

Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects

Jul 202441 participants

A Phase 1, Open-Label, Non-Randomized, Single-Center, Single-Dose Study to Assess the Pharmacokinetics and Safety of ANT3310 Combined with Meropenem Administered as a Single Intravenous Infusion to Adult Subjects with Renal Function Impairment

Active, not recruiting

May 202448 participants

FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects

Apr 202372 participants

Approvals

No approval data available

News

Antabio's MEM-ANT3310 Completes Phase 1 Trial, Showing Promise Against Multidrug-Resistant Infections

- Antabio's MEM-ANT3310, a novel antibacterial combination, has successfully completed its Phase 1 clinical trial in healthy volunteers, demonstrating good tolerability. - The trial assessed the safety, tolerability, and pharmacokinetics of ANT3310, a serine-beta-lactamase inhibitor, both alone and in combination with meropenem. - Results indicate that ANT3310 was well-tolerated with no serious adverse events and exhibited compatible pharmacokinetics with meropenem, supporting further patient studies. - MEM-ANT3310 is designed to combat antimicrobial resistance in severe hospital infections, particularly those caused by Gram-negative pathogens like CRAB, CRE, and Pseudomonas aeruginosa.

On this page

Overview
Clinical Trials6
Approvals
News1

Back to Organizations